Lenstec Completes Enrollment of FDA Trial for SBL-3 IOL

Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast sensitivity, and minimizes the halos and glare (dsyphotopsias) commonly associated with other traditional concentric traditional multifocal presbyopia-correcting IOLs, according to Lenstec.

Utilizing segmented bi-aspheric optic technology, the SBL-3 has two refracting surfaces to capture light differently to the retina, for near and distance vision. Lenstec’s patented four-point fixation shape design, and 0.25 diopter power increments enable improved effective lens positioning and visual outcomes.

Upon successful completions of these trials and final FDA approval, the SBL-3 would be the first segmented non-concentric bifocal IOL in the United States.